Ministry of Health, Uganda

Introduction

It can be used to:

· Identify challenges and recommendations to avert supply interruptions· Encourage preparation and sharing of joint supply plans with stakeholders· Identify strategies for regularly reviewing supply plans for all the commodities· Encourage donors to honor their commitments in terms of quantities of products expected, timeliness of deliveries and flexibility.#NAME?

Summaries of the Central Inventory Level Stock Status Risk of stockout

Justification

- Acts as an early warning indicator for potential stock outs and possible expiries of EMHS.

STOCK STATUS REPORT AS AT 1ST JULY 2012For actual of dates of data collection, refer to the detail for each commodity

The purpose of this report is to inform Ministry of Health officials especially program managers and all stakeholders of the stock levels in the country in order for appropriate logistics decisions to bemade and implemented. This report highlights challenges, bottlenecks and recommends potential solutions to mitigate stock outs and expiries of ARVs & HIV test kits, ACTs, Anti-TB medicines,Reproductive Health items, selected Laboratory commodities and selected medicines for opportunistic infections.

M in M ax

Questions or clarifications? Email to pharmacy@health.go.ug This report was made with Technical Assistance from the USAID/ SURE Program

outACTs

NMS has stocked out of the 24 pack,18 pack and 12 pack while the 6pack is alsobelow the minimum stock level. Available information indicate that no AL in the NMSpipeline for the ACTS and Quality Chemicals contract not yet renewed. JMS stocklevels for all pack sizes are stable. Since NMS supplies the majority of health facilitiesin Uganda, there is need to urgently place an order to avert possible crisis.

Other antimalarials

The stock level of Inj. Quinine still remains at below minimum level. NMSstill calls offstocks from the framework contract. The policy change to use Artesunate in favour ofQuinine injection has been ratified. Risk of stock out

Artesunate injection is not yet stocked at NMS and JMS. NMS has just initiated theprocurement process following the MOH policy change from Quinine to Inj. Artesunatefor the management of severe malaria. The donation from the Peoples Republic of

HIGH

0 2 4 6 8

Artemether-Lumefantrine20/120mg tab (Green), 24 pack*

Artemether-Lumefantrine20/120mg tab (Brown), 18 pack*

Artemether-Lumefantrine20/120mg tab (Blue), 12 pack*

Artemether-Lumefantrine20/120mg tab (Yellow), 6 pack*

Artesunate Injection 60mg/ml with Sodium bicarbonate diluents

Quinine HCl injection, 600mg/2ml ampoule

Sulphadoxine-Pyrimethamine500/25mg tab*

SoH

Pipeline

M in M ax

for the management of severe malaria. The donation from the Peoples Republic ofChina is expected to arrive in September.

Sulphadoxine/ Pyrimethamine (SP) stocks at NMS are now stable. JMS currently isstocked out of SP for the intermittent presumptive treatment of malaria in pregnancy.

ARVs for adults

For the first time now, we received ARV data from MAUL (for CDC partners) giving usa more holistic scenario of the ARV supply system in Uganda.

A) - First Line Products

NMS stock levels of all first-line ARVs are below the minimum stock level althoughpipeline is appearing relatively fine . JMS is still stocked out of public-sectorAZT/ 3TC/NVP AND AZT/3TC. However Buffer stocks from USG throughPEPFAR continue to bridge the gap especially in PNFP Facilities Global Fund

3.5

1.3

0.0

4.2

1.2

5.2

1.2

7.6

0.0

5.7

3.3

0.0

TDF/3TC 300mg/300mg

EFV 600mg

LPVr 200/50mg

ABC 300mg

DDI 250mg

DDI 400mg

AZT 300mg

ARVs for Adults

SoH

Pipeline

M in M ax

0 2 4 6 8

Artemether-Lumefantrine20/120mg tab (Green), 24 pack*

Artemether-Lumefantrine20/120mg tab (Brown), 18 pack*

Artemether-Lumefantrine20/120mg tab (Blue), 12 pack*

Artemether-Lumefantrine20/120mg tab (Yellow), 6 pack*

SoH

Pipeline

PEPFAR continue to bridge the gap especially in PNFP Facilities. Global Fundprocurements to replenish JMS of these products are expected in August 2012.Orders from Quality Chemicals not yet confirmed. Stock levels for NVP andTDF/3TC are below minimum posing a risk of stock insufficiencies. PEPFAR emergency procurement expetced since July will deliver 1MOS of TDF/3TC and5MOS of NVP to NMS. MAUL stock levels are healthy except for TDF/3TC abovemaximum (8.9MOS) and AZT/3TC (0.6MOS) .

MMEDMEDIUM

Consumption for TDF has continued to rise, due to a policy change which wassubsequently halted until further commodity is available. However, patients whohave switched to TDF have appropriately remained on TDF. An emergencyPEPFAR procurement for an additional 4 months of stock is expected, but thedelivery date is unknown. Extremely high risk of stock-out

The on-going discussion on how to improve availability of these products to thePNFP sector is almost complete. The rationalization team under MoH will becompleting the exercise by end of June 2012. PEPFAR continues to providetemporary support to the PNFPs/PFPs and limiited amount of facility level buffering

4.3

4.1

3.2

3.5

1.3

0.0

4.2

5.8

3.8

7.1

1.2

7.6

0.0

5.7

0 4 8 12

AZT/3TC/NVP 300/150/200mg

AZT/3TC 300/150mg

NVP 200mg

TDF/3TC 300mg/300mg

EFV 600mg

LPVr 200/50mg

ABC 300mg

g

SoH

Pipeline

M in M axtemporary support to the PNFPs/PFPs and limiited amount of facility level buffering.

B) - Second Line

The stock levels for all adult second line ARVs are within the recommended max-min range for central level except LPV/r which is still stocked out at JMS andbelow minimum at NMS (2.6MOS). MAUL stock for LPV/r is is healthy (7.2MOS).A PEPFAR emergency procurement will provide 4 months of stock to NMS. JMSremains stocked out with nothing in the pipeline.

MEDIUM

ARVs for ChildrenThe stock level for most of the pediatric ARVs are within the normal Min-max rangefollowing CHAI’s efforts in redistributions and supply plan adjustments.

Paed. AZT/3TC/NVP stock level is close to minimum resulting from an increasedconsumption due to the scale-up plan. PEPFAR committed to provide additional stock.No risk of stock out.

Low forstock out

4.3

4.1

3.2

5.8

3.8

7.1

0 4 8 12

AZT/3TC/NVP 300/150/200mg

AZT/3TC 300/150mg

NVP 200mg

4.4

22.7

6.1

4.6

5.6

14.6

22.8

0.0

0.8

0.3

3.3

0.0

0.0

0.0

0.0

4.4

0.0

0 4 8 12

ABC 20mg/ml

ABC/3TC 60/30mg

EFV 50mg

AZT/3TC 60/30mg

AZT/3TC/NVP 60/30/50mg

D4T/3TCP 6/30mg

D4T/3TC/NVP 6/30/50mg

3TC 50mg/ml

D4T/3TC 12/60mg

LPVr 80/20mg

NVP 50mg/ml

ARVs for Children

SoH

Pipeline

M in M ax

NVP 50mg/ml is now reserved for PMTCT- No risk of stock out. NVP 50mg tablet toreplace the syrup for use in HIV treatment.

4.4

22.7

6.1

4.6

5.6

14.6

3.3

0.0

0.0

0.0

0 4 8 12

ABC 20mg/ml

ABC/3TC 60/30mg

EFV 50mg

AZT/3TC 60/30mg

AZT/3TC/NVP 60/30/50mg

D4T/3TCP 6/30mg

/3T /N 6/30/50mg

SoH

Pipeline

Questions or clarifications? Email to pharmacy@health.go.ug This report was made with Technical Assistance from the USAID/ SURE Program

Ministry of Health, Uganda

NVP 50mg/ml is now reserved for PMTCT- No risk of stock out.. NVP 50mg tablet toreplace the syrup for use in HIV treatment.

In their efforts to increase efficiency and effectiveness in providing ART, MOH andPartners have finalised the supply rationalisation discussion and the official launch ofthe process is expcted to take place soon.

Laboratory CommoditiesLaboratory commodities still present a fluctuating situation. There is still difficulty inmaintaining the minimum-maximum levels due to challenges in both supply anddemand. With support from the SURE program, laboratory assessment exercise willresume in the month of August 2012 to review laboratory logistics indetails.Establishing actual AMC for some lab items is still a challenge.

A) - HIV Test Kits and disease monitoring supplies

M in axM in M ax

A) - HIV Test Kits and disease monitoring suppliesConsumption data of most test kits HAS SHOT UP DUE TO VARIOUS PROGRAMSTHAT HAVE HIV TESTING AS PRERQUISITE.(PMTCT,PITC,SMC ETC). Stocks inthe country and pipeline are healthy with impending deliveries from Global Fund. Havestopped Ips from procuring buffer stock in the spirit of harmonisation. All Ips are pullingfrom NMS using the facility whre they work. No fear of overstocking as the Ministry hasstopped Ips from procuring buffer stock in the spirit of harmonisation.IPs will instead

B) - Malaria Rapid Diagnostic Test Kits LOWRDTs are currently at 2.4MOS with 3.0MOS from AMFm expected in August 2012. TheNMCP and pharmacy monitor the roll-out strategy and overall supply plan for theRDTs to avoid potential expiries if all the AMFm orders are to be delivered.

C) - Other Laboratory commodities

Facs Count and Pertek kits for CD4 count are still stocked out. 6.3MOS of perteckexpected in August 2012.

Anti TB Medines 12.0

12.0

12.0

12.0

12.0

12.0

LEVOFLOXACIN 250M G TABLETS

M OXIFLOXACIN 400M G TABLETS

PASER 4 GM SACHETS

Anti-TB Medicines - Months of Stock

SoH PipelineM in M ax

RHZE tablet 75/150/275/400/ mg : Stock levels at central level are below the minimumlevel yet this product accounts for over 60% of all current load of TB ptients. NMS is inthe process of clearing a shipment from GDF to cover roughly a 6 month period.

EH two-week blister strip 400/150 mg : This product is stocked out at central levelstocks are at facility level. GDF is sending a 6 months stock by September 2012 . Highrisk of stock-out at health facility level if delivery is delayed

HIGH

Current stocks of Sreptomycin Inj and RHZ Paed are below minimum and are at highrisk of stockout if no shipments come in with two months. Current stocks are belowminimum and are at high risk of stockout if no shipments come in with two months

The central level has more than adequate stocks, the concern is the usage of thismedicine which expires in December 2013 .The NTLP is in talks with the variouspartners across the country to identify pediatric patients and increase reporting athealth facilities for the medicine High risk of expiry if the usage is not increased

3.7

1.1

0.0

43.2

12.1

7.0

3.2

8.0

12.0

12.0

8.0

12.0

7.4

6.2

0.0

5.5

6.5

12.0

12.0

12.0

12.0

12.0

0 4 8 12 16 20

RHZE tablet 75/150/275/400/ mg

EH two-week blister strip 400/150 mg

RH (Adult) tablet

RH (Pediatric) tablet

RHE (75/150/275 mg)

RHZ(Pediatric) tablet 60/30/75 mg

Streptomycin vial 1g

CAPREOM YCIN 1G VIALS

CYCLOSERINE 250M G TABLETS

ETHIONAM IDE 250M G TABLETS

KANAM YCIN 1G VIALS

LEVOFLOXACIN 250M G TABLETS

health facilities for the medicine High risk of expiry if the usage is not increasedsignificantly.

Second -Line TB medicines: NMS has adequate stocks to cater for one hundredpatients and part of these stocks have been distributed to ear-marked regionalhospitals.GDF consignment is expected in September which will cover the balance ofidentified patients on MDR treatment for the full duration of treatment

3.7

1.1

0.0

43.2

12.1

7.0

7.4

6.2

0.0

5.5

0 4 8 12 16 20

RHZE tablet 75/150/275/400/ mg

EH two-week blister strip 400/150 mg

RH (Adult) tablet

RH (Pediatric) tablet

RHE (75/150/275 mg)

RHZ(Pediatric) tablet 60/30/75 mg

Months of Stock

RH CommoditiesThese items are funded by USAID, UNFPA, MoH, WB and Global Fund Round 7 no-cost extension (for the male and female condoms). The Contraceptive Supply Plan for the country hasbeen developed and different partners are committing to selected products.

Alternative channel for distribution of Contraceptives to the private sector through Uganda Health Marketing Group (UHMG) has started working and is expected to decongest thepublic sector supply backlog in the next few months.

Emergency contraceptive pill and Misoprostol are still over stocked despite use of alternative supply channel from UHMG. Iit is advisable to halt new procurements until NMS isdecongested of the excess stockNMS continues procuring mama kits just-in-time under the framework contracts but reports that the demand for maama kits is higher than the current AMC, of 25,000 which is not meeting the country’sneed They expressed need for support by procuring additional mama kits to meet the country’s needsneed. They expressed need for support by procuring additional mama kits to meet the country’s needs.

Questions or clarifications? Email to pharmacy@health.go.ug This report was made with Technical Assistance from the USAID/ SURE Program

Ministry of Health, Uganda

RH COMMODITIES

LOW

Implants (Implanon & Jadelle)*

IUD - Copper Containing Device TCU380A**

Combined Oral Contraceptives (M icrogynon)**

Progestin-only oral contraceptives (M icrolut)[Norgestrel …

M ale Condoms

M anual Vacuum Aspiration (M VA) Double Valve**

M ama Kit**

Female Condom**

Gynaecological gloves

SoH

Pipeline

Questions or clarifications? Email to pharmacy@health.go.ug This report was made with Technical Assistance from the USAID/ SURE Program

Other Medicines for HIV Opportunistic infectionsFluconazole tablets- all formulations adequately stocked No risk of expiry. Stock levelsfor Cotrimoxazole 960mg – Currently stocked out. Next expected from VPP in October2012. high Cotrimoxazole

960mg stocked out

HSSIP TRACER MEDICINES AND COMMODITIES

HSSIP Tracer Medicines and CommoditiesStock levels for the products remain low excccept for ORS and Sulphadoxine/Pyrimethamine. Artemether/ Lumefantrine (24 pack) is completely stocked out atNMS with no information on pipeline.

HIGH AL 24 PACKSTOCKED OUT

Oral Rehydration Salts for 1 Litre

M easles Vaccine

0 10 20 30 40 50 60 70

Depo-Provera

Implants (Implanon & Jadelle)*

IUD - Copper Containing Device TCU380A**

Combined Oral Contraceptives (M icrogynon)**

Progestin-only oral contraceptives (M icrolut)[Norgestrel …

M ale CondomsSoH

Pipeline

Current stock at 4.3 MOS with no risk of stock out following the mass immunisationcampaigne in May 2012. No Measles vaccine in the pipeline.

Data SourcesData on stocks was collected from NMS, JMS, , MAUL, CHAI, GF(FCO), SCMS, UNEPI and UHMG

0 2 4 6 8

Artemether-Lumefantrine20/120mg tab (Green),…

Sulphadoxine-Pyrimethamine…

Cotrimoxazole 480mg

Oral Rehydration Salts for 1 Litre

M easles Vaccine

SoH

Pipeline

Questions or clarifications? Email to pharmacy@health.go.ug This report was made with Technical Assistance from the USAID/ SURE Program

AC

Ts a

nd o

ther

Mal

aria

Med

icin

es (

Max

MO

S: 6

, M

in M

OS

: 4 fo

r ce

ntra

l lev

el)

*A

vera

ge M

onth

ly C

onsu

mpt

ion

is e

stim

ated

usi

ng N

MS

and

JM

S is

sues

dat

a fo

r las

t fou

r mon

ths

Ave

rage

Mon

thly

Con

sum

ptio

n is

est

imat

ed u

sing

NM

S a

nd J

MS

issu

es d

ata

for l

ast f

our m

onth

s

Ave

rage

Mon

thly

Con

sum

ptio

n is

est

imat

ed u

sing

NM

S a

nd J

MS

issu

es d

ata

for l

ast f

our m

onth

s

Tota

lE

stim

ated

Est

imat

edM

onth

sof

Des

crip

tion

Uni

tIn

vent

ory

NM

Sat

1stJ

uly

2012

Inve

ntor

yJM

Sat

1stJ

uly

2012

Tota

lIn

vent

ory

(Cen

tral

Leve

l)

Est

imat

edA

vera

geM

onth

lyC

onsu

mpt

ion

Est

imat

edM

onth

sof

Sto

ck(C

entr

alLe

vel)

Qua

ntity

onO

rder

Mon

ths

ofS

tock

onO

rder

Exp

ecte

dD

eliv

ery

Dat

eC

omm

ents

Arte

met

her-

Lum

efan

trine

20/

120m

g

The

prod

ucti

sal

mos

tsto

cked

out

atN

MS

whi

le J

MS

st

ock

leve

l is

stab

le th

ough

they

have

a s

hort

expi

ryw

ith

one

batc

h ex

pirin

g in

Nov

embe

r 201

2 an

d th

e se

cond

ba

tch

expi

res

in J

une

2012

.Th

ere

isne

ed to

urg

ently

1A

rtem

ethe

r-Lu

mef

antri

ne 2

0/12

0mg

tab

(Gre

en),

24 p

ack*

30 S

trips

5,50

112

,827

1

8,32

8

37,

649

0.5

pire

sur

gent

lypl

ace

an o

rder

to a

vert

poss

ible

sto

ckou

t.S

tock

edou

t at

NM

S a

ndst

ocks

sta

ble

at J

MS

.com

mod

ityst

ocke

dou

t sin

ce N

MS

sup

plie

s th

e m

ajor

ityof

hea

lthfa

cilit

ies

inth

e co

untr

y

2A

rtem

ethe

r-Lu

mef

antri

ne 2

0/12

0mg

30 S

trips

12

1

0,57

6

10,

588

1

6,32

1 0.

6

NM

S h

asst

ocke

d ou

toft

his

com

mod

ityho

wev

er J

MS

st

ock

isst

ill s

tabl

e.Th

ere

isne

ed to

urg

ently

plac

e an

or

der a

tNM

S to

ave

rtpo

ssib

le s

tock

outs

ituat

ion.

2A

rtem

ethe

r-Lu

mef

antri

ne 2

0/12

0mg

tab

(Bro

wn)

, 18

pack

*30

Stri

ps12

10,

576

1

0,58

8

16,

321

0.6

Sto

cked

out

3A

rtem

ethe

r-Lu

mef

antri

ne 2

0/12

0mg

tab

(Blu

e), 1

2 pa

ck*

30 S

trips

16

7,9

25

7,9

41

1

5,90

8 0.

5N

MS

has

stoc

ked

outo

fthi

sco

mm

odity

how

ever

JM

S

stoc

kis

still

sta

ble.

Ther

e is

need

to u

rgen

tlypl

ace

an

orde

r atN

MS

to a

vert

the

situ

atio

n.S

tock

ed o

ut

Pro

duct

stoc

kle

vel i

sbe

low

min

imum

leve

l.Th

ere

isne

ed

to u

rgen

tlypl

ace

an o

rder

to a

vert

poss

ible

sto

ckou

t.4

Arte

met

her-

Lum

efan

trine

20/

120m

g ta

b (Y

ello

w),

6 pa

ck*

30 S

trips

1

15,3

97

38,

571

15

3,96

8

47,

923

3.2

to u

rgen

tlypl

ace

an o

rder

to a

vert

poss

ible

sto

ckou

t.R

isk

of S

tock

out

5A

rtesu

nate

Inje

ctio

n 60

mg/

ml w

ith

Sod

ium

bic

arbo

nate

dilu

ents

V

ial

-

-

-

Arte

suna

te in

ject

ion

isno

tyet

stoc

ked

atN

MS

and

JM

S.

Pol

icy

chan

ge fr

omQ

uini

ne to

Arte

suna

te fo

r sev

ere

mal

aria

has

been

pas

sed

byth

e M

oH.A

tran

sitio

n pl

an

has

been

dev

elop

ed to

gui

de N

MS

and

JM

S in

ens

urin

g st

abili

tyin

sto

cksi

tuat

ion.

stab

ility

in s

tock

situ

atio

n.

6Q

uini

ne H

Cl i

njec

tion,

600

mg/

2ml

ampo

ule

100

5,

046

-

5,

046

2,2

45

2.2

The

stoc

kle

vel o

fQui

nine

stil

l rem

ains

atbe

low

min

imum

leve

l.N

MS

still

cal

lsof

fsto

cks

from

the

fram

ewor

kco

ntra

ct.T

he p

olic

ych

ange

to u

se o

fArte

suna

te in

favo

ur

ofQ

uini

ne in

ject

ion

has

been

ratif

ied.

Ris

kof

stoc

kou

t

8S

ulph

adox

ine-

Pyr

imet

ham

ine

500/

25m

g ta

b*10

00 ta

b

7,20

8

-

7,20

8

1

,010

7.

17M

OS

wor

th o

fsto

ckis

expe

cted

to b

e ca

lled-

offf

rom

the

NM

S fr

amew

ork

cont

ract

.No

risk

ofst

ocki

ng o

ut.

Que

stio

ns o

rcla

rific

atio

ns?

Em

ailt

oph

arm

acy@

heal

th.g

o.ug

HIV

/AID

SCo

mm

odit

ies

Stoc

kSt

atus

asof

1st

May

2012

AM

C=

Aver

age

Mon

thly

Cons

umpt

ion;

NM

S=

Nat

iona

lMed

ical

Stor

es;

JMS

=Jo

intM

edic

alSt

ores

Des

crip

tion

Uni

tIn

vent

ory

NM

Sat

1stJ

uly

2012

Inve

ntor

yJM

Sat

1stJ

uly

2012

Inve

ntor

yM

AU

L1s

tJul

y20

12

Tota

lInv

ento

ry(C

entr

alLe

vel)

Est

imat

edA

vera

geM

onth

lyC

onsu

mpt

ion

July

NM

SA

MC

July

JMS

AM

CJu

lyM

AU

LA

MC

Est

imat

edM

onth

sof

Sto

ck(T

otal

Sys

tem

)Q

uant

ityon

Ord

erM

onth

sof

Sto

ckon

Ord

er

Exp

ecte

dD

eliv

ery

Dat

eC

omm

ents

AA

dult

Form

ulat

ions

Firs

t Lin

e P

rodu

cts

Lam

ivud

ine

150m

g +

Zido

vudi

ne 3

00m

g +

Nev

irapi

ne 2

00m

g ***

6040

9,73

00

15,7

7142

5,50

199

,038

95,9

200

3,11

84.

357

5,36

4.0

5.8

Jul-2

012

A la

rge

glob

al fu

nd o

rder

is e

xpec

ted

in J

uly

for b

oth

NM

S

and

JMS

whi

ch w

ill c

reat

e a

stab

le s

uppl

y si

tuat

ion.

JM

S

rem

ains

sto

cked

out

Lam

ivud

ine1

50m

g +

Zido

vudi

ne 3

00 M

g T

ab**

6017

3,22

50

4,72

317

7,94

843

,515

35,7

500

7,76

54.

116

4,29

2.0

3.8

Jul-2

012

Of t

he s

tock

in th

e pi

pelin

e, 1

13 0

00 p

acks

are

exp

ecte

d in

Ju

l 201

2 fro

m G

loba

l Fun

d fo

r NM

S a

nd J

MS

. The

bal

ance

w

ill c

ome

in A

ugus

t 201

2. J

MS

is s

tock

ed o

ut.

Nev

irapi

ne 2

00m

g T

ab**

6079

,814

068

,579

148,

393

46,1

6531

,265

014

,900

3.2

326,

344.

07.

1Ju

l-201

2

Alth

ough

sto

ck le

vels

are

at a

bar

e m

inim

um, N

MS

will

be

reci

eivi

ng 5

mon

ths

of s

tock

from

a P

EP

FAR

em

erge

ncy

proc

urem

ent.

Glo

bal F

und

proc

urem

ents

will

als

o pr

ovid

e a

heal

thy

pipe

line,

with

43

000

pack

s go

ing

to J

MS

. JM

S

rem

ains

sto

cked

out

.

TD

F/3T

C 3

00/3

00m

g T

abs*

*30

42,6

4235

,966

213,

502

292,

110

82,7

2858

,051

681

23,9

963.

510

0,44

0.0

1.2

Jul-2

012

Con

sum

ptio

n fo

r TD

F ha

s co

ntin

ued

to ri

se, d

ue to

a p

olic

ych

ange

whi

ch w

as s

ubse

quen

tly h

alte

d un

til fu

rther

co

mm

odity

is a

vaila

ble.

How

ever

, pat

ient

s w

ho h

ave

switc

hed

to T

DF

have

app

ropr

iate

ly re

mai

ned

on T

DF.

An

emer

genc

y P

EP

FAR

pro

cure

men

t for

an

addi

tiona

l 4

mon

ths

of s

tock

is e

xpec

ted,

but

the

deliv

ery

date

is

unkn

own.

E

xtre

mel

y hi

gh ri

sk o

f sto

ck-o

ut

Efa

vire

nz 6

00m

g T

ab**

300

064

,267

64,2

6750

,709

37,4

777

13,2

251.

338

6,84

6.0

7.6

Jul-2

012

Cur

rent

ly s

tock

ed o

ut a

t bot

h JM

S a

nd N

MS

. How

ever

, an

emer

genc

y P

EP

FAR

pro

cure

men

t is

expe

cted

to p

rovi

de 3

m

onth

s w

orth

of s

tock

at N

MS

and

Glo

bal F

und

proc

urem

ents

are

exp

ecte

d to

pro

vide

ano

ther

4 m

onth

s w

orth

of s

tock

. Sto

cked

out

Sec

ond

Line

Pro

duct

s

Lopi

navi

r 200

mg+

Rito

navi

r 50

mg

Tab

(LP

V/r)

**12

014

,940

1,14

719

,008

35,0

958,

322

5,69

10

2,63

14.

247

,220

.05.

7Ju

l-201

2A

PE

PFA

R e

mer

genc

y pr

ocur

men

t will

pro

vide

4 m

onth

s of

st

ock

to N

MS

. JM

Sre

mai

nsst

ocke

dou

t.

Aba

cavi

r Sul

fate

Tab

lets

30

0mg*

*60

121

260

756

1,13

796

983

472

631.

23,

228.

03.

3A

ug-2

012

Em

erge

ncy

stoc

k is

bei

ng b

roug

ht in

by

UN

ITA

ID

Did

anos

ine

250m

g T

ab**

303,

437

736

04,

173

6654

120

63.2

0.0

0.0

Use

of t

his

prod

uct i

s no

long

er p

refe

rred

as

per t

he

treat

men

t gui

delin

es.N

o ri

sk o

f sto

ck-o

ut

Did

anos

ine

400m

g T

ab**

301,

521

194

01,

715

329

246

830

5.2

0.0

0.0

Use

of t

his

prod

uct i

s no

long

er p

refe

rred

as

per t

he

treat

men

t gui

delin

es.N

o ri

sk o

f sto

ck-o

ut

Zido

vudi

ne 3

00m

g T

ab**

6093

,475

33,3

6645

126,

886

8,05

37,

856

192

515

.80.

00.

0G

loba

l Fun

d pr

ocur

emen

t was

can

celle

d. F

ollo

win

g N

AC

re

com

men

datio

n to

mai

ntai

n pa

tient

s on

Opt

ion

A fo

r P

MT

CT

unt

il co

untry

has

suf

ficie

nt fu

nds,

this

pro

duct

will

Ata

zana

vir 3

00 m

g C

apsu

les

305,

760

1,99

81,

155

8,91

381

680

60

1010

.90.

00.

0

No

mor

e or

der e

xpec

ted

for t

his

prod

uct.

The

fixe

d do

se

com

bina

tion

has

been

prio

tized

.Exi

stin

g st

ock

to b

e us

ed in

co

mbi

natio

n w

ith ri

tona

vir f

or n

ew p

atie

nts

seco

nd li

ne

patie

nts.

No

risk

of s

tock

-out

Ata

zana

vir 3

00m

g+R

itona

vir

100

mg

Tab

s30

00

00

0N

/A0

00.

00.

0N

ew p

refe

rred

PI f

or u

se in

2nd

line

in a

dult

patie

nts.

C

onsu

mpt

ion

figur

es y

et to

be

fully

est

ablis

hed.

No

risk

of

stoc

k-ou

t

Rito

navi

r 100

mg

Tab

s60

2,10

850

092

03,

528

375

370

05

9.4

0.0

0.0

No

mor

e or

der e

xpec

ted

for t

his

prod

uct.

The

fixe

d do

se

com

bina

tion

has

been

prio

tized

. .E

xist

ing

stoc

k to

be

used

in

com

bina

tion

with

rito

navi

r for

sec

ond

line

patie

nts.

No

risk

of s

tock

-out

Que

stio

ns o

rcla

rific

atio

ns?

E-m

ail t

oph

arm

acy@

heal

th.g

o.ug

orok

umu.

mor

ris@

heal

th.g

o.ug

HIV

/AID

SCo

mm

odit

ies

Stoc

kSt

atus

asof

1st

May

2012

Des

crip

tion

Uni

tIn

vent

ory

NM

Sat

1stJ

uly

2012

Inve

ntor

yJM

Sat

1stJ

uly

2012

Inve

ntor

yM

AU

L1s

tJul

y20

12

Tota

lInv

ento

ry(C

entr

alLe

vel)

Est

imat

edA

vera

geM

onth

lyC

onsu

mpt

ion

July

NM

SA

MC

July

JMS

AM

CJu

lyM

AU

LA

MC

Est

imat

edM

onth

sof

Sto

ck(T

otal

Sys

tem

)Q

uant

ityon

Ord

erM

onth

sof

Sto

ckon

Ord

er

Exp

ecte

dD

eliv

ery

Dat

eC

omm

ents

BP

edia

tric

For

mul

atio

ns

Aba

cavi

r Sul

fate

Ora

l S

olut

ion

240m

l 20m

g/m

l**24

0ml

1,30

50

01,

305

2727

00

48.3

0.0

0.0

Syr

up is

bei

ng p

hase

d ou

t with

the

intro

duct

ion

of th

e A

BC

60

mg

disp

ersi

ble

tabl

et. N

o ris

k of

exp

iry

Aba

cavi

r 60m

g (d

ispe

rsib

le)

6029

70

029

768

680

04.

430

0.0

4.4

Jul-2

012

New

dis

pers

ible

form

ulat

ion

to re

plac

e A

baca

vir o

ral

solu

tion.

Con

sum

ptio

n fig

ures

yet

to b

e fu

lly e

stab

lishe

d.

Aba

cavi

r/Lam

ivud

ine

60/3

0mg

tab*

*60

20,4

440

3,20

123

,645

660

572

088

35.8

0.0

0.0

Pla

nned

sca

le-u

p is

exp

ecte

d to

incr

ease

con

sum

ptio

n of

th

e pr

oduc

t. O

rder

s in

pip

elin

e ha

ve b

een

canc

elle

d, a

nd

expl

orin

g m

ovin

g th

e st

ock

out o

f cou

ntry

.

Efa

vire

nz 2

00m

g C

ap**

9018

,099

17,6

229,

251

44,9

721,

977

1,60

890

279

22.7

0.0

0.0

Con

sum

ptio

n is

exp

ecte

d to

rise

. Ord

ers

in p

ipel

ine

have

be

en c

ance

lled,

and

exp

lorin

g m

ovin

g th

e st

ock

out o

f co

untry

. La

miv

udin

e 30

mg+

Zido

vudi

ne 6

0mg

Tab

lets

**60

11,6

930

6,66

518

,358

3,02

52,

312

071

36.

113

,790

.04.

6T

he s

cale

-up

plan

has

led

to in

crea

se in

ove

rall

cons

umpt

ion

for t

he p

rodu

ct. P

EP

FAR

will

pro

vide

ad

ditio

nal s

tock

. No

risk

of s

tock

out

Lam

ivud

ine

30m

g+Zi

dovu

dine

60

mg+

Nev

irapi

ne 5

0mg*

*

6020

,122

12,7

5637

,701

70,5

7915

,394

12,9

8510

62,

303

4.6

92,1

61.0

6.0

Jul-2

012

Sta

ble

stoc

k si

tuat

ion.

No

risk

of s

tock

out

Lam

ivud

ine

60m

g+S

tavu

dine

12

mg+

Nev

irapi

ne 1

00m

g**

602,

267

4,13

50

6,40

21,

135

1,04

43

885.

60.

00.

0P

rodu

ct e

xpec

ted

to b

e ph

ased

out

with

all

d4T

FD

Cs

bein

g ha

rmon

ised

aro

und

d4T

/3T

C 6

/30m

g fo

rmul

atio

n. N

o R

isk

of E

xpiry

Lam

ivud

ine

30m

g +

Sta

vudi

ne 6

mg

+ N

evira

pine

50

mg

Tab

***

6041

,177

7,24

13,

812

52,2

303,

584

3,50

65

7314

.60.

00.

0T

he p

rodu

ct is

exp

ecte

d to

take

up

all p

atie

nts

of o

ther

d4T

form

ulat

ions

. The

pip

elin

e ha

s be

en c

ance

lled.

Lam

ivud

ine

30m

g +

Sta

vudi

ne 6

mg

Tab

609,

541

02,

953

12,4

9454

853

00

1822

.851

4.0

0.9

Sto

ck is

abo

ve m

axim

um. C

onsi

der s

tock

mov

emen

t to

othe

r sup

ply

chai

ns. M

ajor

ity o

f pip

elin

e ha

s be

en

canc

elle

d. R

isk

of E

xpiry

Lam

ivud

ine

Ora

l Sol

utio

n 50

mg/

ml**

240m

l0

00

00

00

00.

00.

0S

yrup

has

bee

n ph

ased

out

.

Lopi

navi

r 80m

g +R

itona

vir

20m

g**

5X60

ml

227

010

237

309

309

00

0.8

0.0

0.0

Spi

ke in

con

sum

ptio

n ha

s re

sulte

d in

a lo

w s

tock

situ

atio

n.

Bay

lor w

ill p

rovi

de 1

000

bottl

es to

NM

S. S

tabl

e st

ock

Lopi

navi

r+R

itona

vir

100m

g/25

mg*

*60

2823

149

200

588

397

019

10.

33,

477.

05.

9Ju

l-201

2S

pike

in c

onsu

mpt

ion

has

resu

lted

in a

low

sto

ck s

ituat

ion.

P

ipel

ine

is e

xpec

ted

to b

e on

tim

e. C

urre

ntly

sto

cked

out

.

Nev

irapi

ne 5

0mg/

5ml S

usp*

*24

0ml

599

500

601,

159

445

213

232

02.

60.

00.

0S

yrup

is b

eing

pha

sed

out

Nev

irapi

ne 5

0mg/

5ml S

usp*

*10

0ml

164,

983

20,6

940

185,

677

20,0

9119

,377

714

09.

20.

00.

0U

sed

for P

MT

CT

and

suf

ficie

nt le

vel o

f sto

ck in

cou

ntry

.

Nev

irapi

ne 5

0mg

305,

295

4,00

01,

520

10,8

1551

023

540

235

21.2

0.0

0.0

New

pro

duct

that

will

repl

ace

the

NV

P o

ral s

uspe

nsio

ns.

Con

sum

ptio

n is

bas

ed o

n sc

ale-

up p

lan.

CO

ther

Med

icin

es fo

r O

ppor

tuni

stic

infe

ctio

ns

Fluc

onaz

ole

(Difl

ucan

)**

2836

,653

036

,653

4,93

87.

4

Fluc

onaz

ole

2mg/

ml I

.V.

Infu

sion

100

ml (

Difl

ucan

)**

100m

l1,

988

01,

988

228

8.7

Fluc

onaz

ole

50m

g/5m

l ora

l su

spen

sion

(Difl

ucan

)**

35m

l2,

142

02,

142

334

6.4

Cot

rimox

azol

e 96

0mg

Tab

**10

0011

,411

111

,412

16,4

040.

7S

tock

ed o

ut. N

ext e

xpec

ted

from

VP

P in

Oct

ober

201

2.

Que

stio

ns o

rcla

rific

atio

ns?

E-m

ail t

oph

arm

acy@

heal

th.g

o.ug

orok

umu.

mor

ris@

heal

th.g

o.ug

TBSt

ock

Stat

us 1

stM

arch

2012

Ant

iTB

Med

icin

es(M

axM

OS

:12,

Min

MO

S:6

for

cent

rall

evel

) C

entr

alS

tore

s

*A

vera

ge M

onth

ly C

onsu

mpt

ion

is e

stim

ated

usi

ng c

onsu

mpt

ion

data

from

the

faci

litie

s.A

MC

=Av

erag

e M

onth

lyCo

nsum

ptio

n;N

TLP

=N

atio

nalT

B&

Lep

rosy

Prog

ram

Des

crip

tion

Uni

tIn

vent

ory

at

NM

S (a

s at

Ju

ly 1

, 201

2)

Est

imat

edA

vera

geM

onth

lyC

onsu

mpt

ion

Est

imat

ed

Mon

ths

of

Sto

ck (T

otal

sy

stem

)

Qua

ntity

on O

rder

Mon

ths

of

Sto

ck o

n O

rder

Exp

ecte

d D

eliv

ery

Dat

eC

omm

ents

Sto

ck le

vels

at c

entra

l lev

el a

re b

elow

the

min

imum

leve

l yet

this

pro

duct

Que

stio

nsor

cla

rific

atio

ns?

E-m

ail t

oph

arm

acy@

heal

th.g

o.ug

1R

HZE

tabl

et

75/1

50/2

75/4

00/ m

gB

liste

rs89

,808

2

4,16

43.

7217

8,20

07.

4A

ugus

t 15t

h20

12

Sto

ck le

vels

at c

entra

l lev

el a

re b

elow

the

min

imum

leve

l yet

this

pro

duct

ac

coun

ts fo

r ove

r 60%

of a

ll cu

rren

t loa

d of

TB

ptie

nts.

NM

S is

in th

epr

oces

s of

cle

arin

g a

ship

men

t fro

m G

DF

to c

over

roug

hly

a 6

mon

thpe

riod.

2E

H tw

o-w

eek

blis

ter

strip

400

/150

mg

Blis

ters

28,5

36

26,

780

1.07

165,

480

6.2

Aug

ust 1

5th

to O

ctob

er

15th

, 201

2

Thi

s pr

oduc

t is

stoc

ked

out a

t cen

tral l

evel

sto

cks

are

at fa

cilit

y le

vel.

GD

F is

sen

ding

a 6

mon

ths

stoc

k by

Sep

tem

ber 2

012

. Hig

h ri

sk o

f st

ock-

out a

t hea

lth fa

cilit

y le

vel i

f del

iver

y is

del

ayed

3R

H (A

dult)

tabl

et

Blis

ters

94,6

56Ju

l-201

2

4R

H (P

edia

tric)

tabl

et

Blis

ters

71,0

64

1

,644

43.2

317

5,77

610

6.9

Jul-2

012

The

cen

tral l

evel

has

mor

e th

an a

dequ

ate

stoc

ks, t

he c

once

rn is

the

usag

e of

this

med

icin

e w

hich

exp

ires

in D

ecem

ber 2

013

.The

NT

LP is

inta

lks

with

the

vario

us p

artn

ers

acro

ss th

e co

untry

to id

entif

y pe

diat

ric

patie

nts

and

incr

ease

repo

rting

at h

ealth

faci

litie

s fo

r the

med

icin

eH

igh

risk

of e

xpir

y if

the

usag

e is

not

incr

ease

d si

gnifi

cant

ly.

5R

HE

(75/

150/

275

mg)

Blis

ters

28,1

28

2

,318

12.1

314

3,61

662

.0A

ug-2

012

NM

S re

cent

ly p

rocu

red

stoc

k to

cov

er o

ne y

ear,

GD

F ha

s pe

ndin

gsh

ipm

ents

that

are

exp

ecte

d in

cou

ntry

by

end

of A

ugus

t to

cove

r 12

mon

ths

perio

d. T

his

prod

uct i

s ad

equa

tely

sto

cked

at c

entra

l lev

el

6R

HZ

(Ped

iatri

c)

tabl

et 6

0/30

/75

mg

Blis

ters

15,0

60

2

,139

7.04

11,8

325.

5A

ug-2

012

The

sto

cks

are

bord

erin

g on

the

min

imum

leve

l at c

entra

l lev

el, G

DF

has

supp

lies

to c

over

a fi

ve m

onth

s pe

riod

to b

e ai

rlifte

d w

thin

the

mon

th o

f A

ugus

t. A

larg

er c

onsi

gnm

ent w

ill b

e se

nt in

Nov

embe

r 201

2

269,

300

6.5

Aug

ust a

ndS

epte

mbe

r, 20

12

GD

F sh

ipm

ents

are

exp

ecte

d in

cou

ntry

in A

ugus

t 201

2. C

urre

nt s

tock

sar

e be

low

min

imum

and

are

at h

igh

risk

of s

tock

out i

f no

ship

men

tsco

me

in w

ith tw

o m

onth

s

NM

Spr

ocur

emen

tis

expe

cted

inco

untr

yon

the

20th

Augu

st20

12, i

fcom

bine

dw

ithth

eG

DF

3.19

7S

trept

omyc

in v

ial 1

gV

ial

131,

711

4

1,28

1

54,0

181.

3A

ugus

t, 20

12

NM

Spr

ocur

emen

tis

expe

cted

inco

untr

yon

the

20th

Augu

st20

12, i

fcom

bine

dw

ithth

eG

DF

ship

men

ts e

xpec

ted

inco

untr

yyh

enth

ece

ntra

llev

elsu

pple

is w

illbe

clos

eto

ten

mon

ths

wor

thof

stoc

k.Cu

rren

t sto

cks

are

belo

wm

inim

uman

dar

eat

hig

hri

skof

stoc

kout

ifno

ship

men

tsco

me

inw

ith

two

mon

ths

Des

crip

tion

Uni

tIn

vent

ory

at

NM

S (a

s at

Ju

ly 1

, 201

2)

Est

imat

edA

vera

geM

onth

lyC

onsu

mpt

ion

Est

imat

ed

Mon

ths

of

Sto

ck (T

otal

sy

stem

)

Qua

ntity

on O

rder

Mon

ths

of

Sto

ck o

n O

rder

Exp

ecte

d D

eliv

ery

Dat

eC

omm

ents

8CA

PREO

MYC

IN1G

VIAL

Svi

al10

508.

012

.0G

LCsh

ipm

ents

are

expe

cetd

inco

untr

yby

end

ofSe

ptem

ber2

012

9CY

CLO

SERI

NE

250M

GTA

BLET

Sta

blet

1485

0012

.012

.0G

LCsh

ipm

ents

are

expe

cetd

inco

untr

yby

end

ofSe

ptem

ber2

012

10ET

HIO

NAM

IDE

250M

GTA

BLET

Sta

blet

1395

0012

.012

.0G

LCsh

ipm

ents

are

expe

cetd

inco

untr

yby

end

ofSe

ptem

ber2

012

11KA

NAM

YCIN

1GVI

ALS

vial

1400

8.0

12.0

GLC

ship

men

ts a

reex

pece

tdin

coun

try

byen

dof

Sept

embe

r201

2

12LE

VOFL

OXA

CIN

250M

Gta

blet

1738

0012

012

0G

LCsh

ipm

ents

are

expe

cetd

inco

untr

yby

end

ofSe

ptem

ber2

012

12TA

BLET

Sta

blet

1738

0012

.012

.0G

LCsh

ipm

ents

are

expe

cetd

inco

untr

yby

end

ofSe

ptem

ber2

012

13M

OXI

FLO

XACI

N40

0MG

TABL

ETS

tabl

et47

0012

.012

.0G

LCsh

ipm

ents

are

expe

cetd

inco

untr

yby

end

ofSe

ptem

ber2

012

14PA

SER

4G

M S

ACH

ETS

sach

et62

512

.012

.0G

LCsh

ipm

ents

are

expe

cetd

inco

untr

yby

end

ofSe

ptem

ber2

012

Que

stio

nsor

cla

rific

atio

ns?

E-m

ail t

oph

arm

acy@

heal

th.g

o.ug

Rep

rodu

ctiv

eH

ealth

Item

s(M

axM

OS

:8,

Min

MO

S:4

for

cent

rall

evel

)-B

oth

Pub

lic&

Pri

vate

sect

ors

Ave

rage

Mon

thly

Con

sum

ptio

n is

est

imat

ed u

sing

NM

S p

roje

cted

issu

es q

uant

ities

and

UH

MG

act

ula

issu

es fo

r Jan

-Jun

e 20

12

AM

C=

Ave

rage

Mon

thly

Cons

umpt

ion

Des

crip

tion

Uni

t

Inve

ntor

yat

Nat

iona

lle

vela

sat

June

30,

2012

AM

C

Est

imat

edM

onth

sof

Sto

ck(C

entr

alLe

vel)

Qua

ntity

onO

rder

Mon

ths

ofS

tock

onO

rder

Com

men

ts

Dep

o-P

rove

ra(M

edro

xypr

oges

tero

neA

ceta

te15

0mg/

mlI

NJ)

*V

ial

96,8

6016

3,28

20.

69,

242,

950

56.6

Sto

ck b

elow

min

imum

stoc

k le

velb

utla

rge

quan

titie

s ar

eex

pect

edun

derN

MS

fram

ewor

k co

ntra

cts

Impl

ants

(Im

plan

on&

Jade

lle)*

Pie

ce90

,914

18,0

615.

053

6,02

829

.7S

tock

with

inm

inim

umm

axim

umra

nge.

Larg

equ

antit

ies

expe

cted

unde

rthe

Wor

ldB

ank

IUD

-Cop

perC

onta

inin

gD

evic

eTC

U38

0A**

Pie

ce4,

069

8,22

80.

517

9,06

621

.8S

tock

bel

owm

inim

umst

ock

leve

l.R

eple

nish

men

ts b

eing

done

caut

ious

ly to

avoi

dov

erst

ocki

ngC

ombi

ned

Ora

lCon

trace

ptiv

es

(Mic

rogy

non)

**C

ycle

s72

9,78

530

9,47

32.

493

6,48

03.

0S

tock

bel

owm

inim

umst

ock

leve

l.R

eple

nish

men

ts b

eing

done

caut

ious

ly to

avoi

dov

erst

ocki

ng

Pro

gest

in-o

nly

oral

cont

race

ptiv

es

(Mic

rolu

t)[N

orge

stre

l0.0

75m

g]**

Cyc

le

20,8

404,

227

4.9

117,

000

27.7

Sto

ck b

elow

min

imum

stoc

k le

vel.

Rep

leni

shm

ents

bei

ngdo

neca

utio

usly

toav

oid

over

stoc

king

Mal

eC

ondo

m(5

2MM

with

and

with

out

Logo

)*P

iece

23,3

19,4

406,

296,

345

3.7

98,6

67,0

0015

.7S

tock

bel

owm

inim

umst

ock

leve

l.U

HM

Gan

ticip

ated

topr

ovid

ene

cess

ary

stor

age

tobr

ing

stoc

k le

vels

with

inac

cept

able

rang

eM

anua

lVac

uum

Asp

iratio

n(M

VA

)D

oubl

eV

alve

**K

it-

-8,

000

Sto

ck b

elow

min

imum

stoc

k le

vel

Mam

aK

it **

Kit

1,89

325

,000

0.1

276,

000

Sto

ck b

elow

min

imum

stoc

k le

velb

utla

rge

quan

titie

s ar

eex

pect

edun

derN

MS

fram

ewor

k co

ntra

cts

Fem

ale

Con

dom

**10

0022

7,80

022

9,70

01.

02,

400,

000

10.4

Sto

ck b

elow

min

imum

stoc

k le

vel

Levo

norg

estre

l750

mcg

Tab

(Em

erge

ncy

Con

trace

ptiv

e)**

Pac

k60

1,11

72,

874

209.

2-

0.0

Item

over

stoc

ked

and

atris

k of

expi

ry.C

urre

ntly

,no

furth

ersu

pply

pla

n.

Mis

opro

stol

200m

cgTa

bs**

1Ta

blet

1,63

2,83

062

026

32.2

-0.

0Ite

mov

erst

ocke

dan

dat

risk

ofex

piry

.Cur

rent

ly,n

ofu

rther

supp

ly p

lan.

Gyn

aeco

logi

calg

love

s1

Pai

r90

00

-

NM

SV

ote

116

has

them

onFr

amew

ork

cont

ract

.N

MS

conf

irms

that

they

hav

epl

anne

dpr

ocur

emen

tund

erth

eW

Bfu

nds;

120,

000

pairs

(Lar

ge)a

nd12

0,00

0pa

irs

(med

ium

).

Rep

rodu

ctiv

e H

ealth

Item

s (M

ax M

OS

:8 ,

Min

MO

S :4

for

cent

rall

evel

) - P

riva

te S

ecto

rU

HM

G

Not

e *A

vera

ge M

onth

ly C

onsu

mpt

ion

is e

stim

ated

usi

ng a

djus

tmen

ts to

the

Con

trace

ptiv

e P

rocu

rem

ent T

able

(CP

T) 2

011

**A

vera

ge M

onth

ly C

onsu

mpt

ion

is e

stim

ated

usi

ng N

MS

issu

es d

ata

up to

30/

sept

/201

1A

MC

=Av

erag

e M

onth

lyCo

nsum

ptio

n;U

HM

G=

Uga

nda

Hea

lthM

arke

ting

Gro

up

Des

crip

tion

Uni

tIn

vent

ory

atU

HM

Gas

atJu

ne30

,201

2

Est

imat

edA

vera

geM

onth

lyC

onsu

mpt

ion

Est

imat

edM

onth

sof

Sto

ck(C

entr

alLe

vel)

Qua

ntity

onO

rder

Mon

ths

ofS

tock

onO

rder

Exp

ecte

dD

eliv

ery

Dat

eC

omm

ents

1D

epo-

Pro

vera

(Med

roxy

prog

este

rone

A

ceta

te 1

50m

g/m

l IN

J)*

Via

l

25,6

6013

,282

1.9

2,1

18,5

50

159.

5U

NFP

A is

exp

ecte

d to

del

iver

105

,350

uni

ts o

f Nor

igyn

on. A

noth

er 3

0,00

0 un

its o

f Dep

o-P

rove

ra a

re p

lann

ed fo

r US

AID

spe

cific

pro

ject

s. T

he re

st o

f the

Dep

o-P

rove

ra is

to b

e su

pplie

d by

US

AID

for s

ocia

l mar

ketin

g

2Im

plan

ts (I

mpl

anon

& J

adel

le)*

Pie

ce

13,7

2210

,561

1.3

2

72,6

56

25.8

UN

FPA

to p

rovi

de 6

1,31

6 im

plan

on E

TA

Jul

y 20

12; U

SA

ID to

pro

vide

pro

ject

spe

cific

sup

plie

s (ja

delle

) and

DFI

D to

pro

vide

pro

ject

spe

cific

sup

plie

s (ja

delle

, im

plan

on a

nd s

ino

impl

ants

). S

uppl

y of

impl

ants

bel

ow d

eman

d th

roug

h th

e pr

ivat

e se

ctor

. A to

tal o

f 100

,000

impl

ants

ne

eded

to b

ring

the

stoc

k le

vels

at U

HM

G to

the

max

imum

of 9

mon

ths.

Not

e th

at th

is q

uant

ityis

arr

ived

at f

ollo

win

g th

e A

MC

der

ived

in a

tim

e w

hen

supp

lies

have

bee

n lim

ited.

3IU

D -

Cop

per C

onta

inin

g D

evic

e T

CU

380A

**P

iece

-

6,3

28

0.0

1

69,0

66

26.7

UN

FPA

to p

rovi

de 7

6,89

6 IU

Ds

ET

A J

uly

2012

; US

AID

and

DFI

D to

pro

vide

pro

ject

spe

cific

IU

Ds.

Sup

ply

antic

ipat

ed to

be

suffi

cien

t.

4C

ombi

ned

Ora

l Con

trace

ptiv

es

(Mic

rogy

non)

**C

ycle

s72

9,78

5

274

,473

2.

7

726

,480

2.

6

Focu

s ha

s be

en o

n re

dist

ribut

ing

in c

ount

ry s

tock

and

ther

e is

no

Mic

rogy

non

inte

nded

for f

ree

dist

ribut

ion

that

is y

et s

ched

uled

for d

eliv

ery

. All

inco

mm

ing

supp

lies

prov

ided

by

US

AID

for

proj

ect s

peci

fic s

uppl

ies

incl

udin

g th

ose

for s

ocia

l mar

ketin

g. A

sses

the

situ

atio

n to

asc

erta

in

whe

ther

inco

untry

sto

ck o

f fre

e m

icro

gyno

n is

stil

l suf

ficie

nt.

5P

roge

stin

-onl

y or

al c

ontra

cept

ives

(M

icro

lut)[

Nor

gest

rel 0

.075

mg]

**C

ycle

20,8

40

727

28

.7

96

,000

13

2.1

Focu

s ha

s be

en o

n re

dist

ribut

ing

in c

ount

ry s

tock

and

ther

e is

no

Mic

rolu

t int

ende

d fo

r fre

e di

strib

utio

n th

at is

yet

sch

edul

ed fo

r del

iver

y . A

ll in

com

min

g su

pplie

s pr

ovid

ed b

y U

SA

ID fo

r pr

ojec

t spe

cific

sup

plie

s. A

sses

the

situ

atio

n to

asc

erta

in w

heth

er in

coun

try s

tock

of f

ree

mic

rogy

non

is s

till s

uffic

ient

.

6M

ale

Con

dom

(52M

M w

ith a

nd w

ithou

t Lo

go)*

P

iece

18,3

84,1

28

1

,296

,345

14

.2

98,

667,

000

76.1

UN

FPA

is to

pro

vide

a to

tal o

f 57,

168,

000

ET

A 1

3m in

Jul

y 20

12, 2

2m in

Aug

ust &

Dec

embe

r 20

12 fo

r fre

e di

strib

utio

n to

the

publ

ic. G

loba

l Fun

d pl

anne

d to

pro

vide

23m

for s

ocia

l m

arke

ting

ET

A J

uly

2012

and

Nov

201

2 bu

t thi

s w

ill b

e re

sche

dule

d on

con

firm

atio

n by

Glo

bal

Fund

. US

AID

to p

rovi

de 3

0m s

tarti

ng A

ugus

t 201

2. T

he re

st o

f the

con

dom

s w

ill b

e pr

ovid

ed

by U

SA

ID fo

r soc

ial m

arke

ting

7M

anua

l Vac

uum

Asp

iratio

n (M

VA

) D

oubl

e V

alve

**K

it

2

,400

U

NFP

A re

ques

ted

to p

rovi

de 2

400

piec

es E

TA

Jun

e 20

12 b

ut h

ave

not y

et d

eliv

ered

. A

MC

es

timat

ed a

t 200

. 12

mon

ths

quan

titie

s pl

anne

d an

d w

ill b

e re

view

ed a

ccor

ding

ly

Mam

a K

it**

Kit

The

re is

nee

d fo

r mam

a ki

ts in

the

priv

ate

sect

or b

ut n

o fu

nds

have

bee

n id

entif

ied

for t

his

so

far.

8Fe

mal

e C

ondo

m**

1000

227,

800

1

61,7

00

1.4

2,4

00,0

00

14.8

UN

FPA

to p

rovi

de fo

r fre

e di

strib

utio

n to

the

publ

ic

9Le

vono

rges

trel 7

50 m

cg T

ab

(Em

erge

ncy

Con

trace

ptiv

e)**

Pac

k10

,014

8

73

11.5

-

0.0

Pre

ferr

able

if e

xces

s N

MS

sto

ck u

sed

befo

re n

ew p

rocu

rem

ent

10M

isop

rost

ol 2

00m

cg T

abs*

* 1

Tab

let

5,09

0

568

9.

0P

refe

rrab

le if

exc

ess

NM

S s

tock

use

d be

fore

new

pro

cure

men

t

Rep

rodu

ctiv

e H

ealth

Item

s (M

ax M

OS

:8 ,

Min

MO

S :

4 fo

rce

ntra

llev

el) -

Pub

lic S

ecto

r(N

MS

)

Not

e *A

vera

ge M

onth

ly C

onsu

mpt

ion

is e

stim

ated

usi

ng a

djus

tmen

ts to

the

Con

trace

ptiv

e P

rocu

rem

ent T

able

(CP

T) 2

011

**A

vera

ge M

onth

ly C

onsu

mpt

ion

is e

stim

ated

usi

ng N

MS

issu

es d

ata

up to

30/

sept

/201

1

AM

C=

Aver

age

Mon

thly

Cons

umpt

ion;

NM

S=

Nat

iona

lMed

ical

Stor

es

Est

imat

ed

Que

stio

ns o

rcla

rific

atio

ns?

E-m

ail t

oph

arm

acy@

heal

th.g

o.ug

orok

umu.

mor

ris@

heal

th.g

o.ug

Des

crip

tion

Uni

tIn

vent

ory

atN

MS

asat

June

30,2

012

Est

imat

edA

vera

geM

onth

lyC

onsu

mpt

ion

Mon

ths

ofS

tock

(Cen

tral

Leve

l)

Qua

ntity

onO

rder

Mon

ths

ofS

tock

onO

rder

Exp

ecte

dD

eliv

ery

Dat

eC

omm

ents

1D

epo-

Pro

vera

(Med

roxy

prog

este

rone

A

ceta

te 1

50m

g/m

l IN

J)*

Via

l0.

5

7

,124

,400

47

.5N

MS

Vot

e 11

6 9

46,8

00 E

TA

29/

Feb/

201

2; a

nd 2

,277

, 600

ET

A 0

1 Ju

ly 2

012.

Wor

ld B

ank

ET

A 3

,900

,000

71,2

0015

0,00

0

2Im

plan

ts (I

mpl

anon

& J

adel

le)*

Pie

ce

77,1

927,

500

10.3

2

63,3

72

35.1

NM

S V

ote

116

1500

0 E

TA

Jul

y 1,

201

2 ; W

orld

Ban

k 24

8372

ET

A D

ec, 2

012

3IU

D -

Cop

per C

onta

inin

g D

evic

e T

CU

380A

**P

iece

4,0

69

1,9

00

2.1

10,0

00

5.3

Item

s pr

ovid

ed b

y U

SA

ID, u

nder

goin

g cl

eara

nce

4C

ombi

ned

Ora

l Con

trace

ptiv

es

Cyc

les

35,0

00

2

10,0

00

Item

s pr

ovid

ed b

y U

SA

ID, u

nder

goin

g cl

eara

nce

4C

ombi

ned

Ora

l Con

trace

ptiv

es

(Mic

rogy

non)

**C

ycle

s-

35,0

00

2

10,0

00

Item

s pr

ovid

ed b

y U

SA

ID, u

nder

goin

g cl

eara

nce

5P

roge

stin

-onl

y or

al c

ontra

cept

ives

(M

icro

lut)[

Nor

gest

rel 0

.075

mg]

**C

ycle

-

3

,500

21

,000

Ite

ms

prov

ided

by

US

AID

, und

ergo

ing

clea

ranc

e

6M

ale

Con

dom

(52M

M w

ith a

nd w

ithou

t Lo

go)*

P

iece

4,93

5,31

2

5

,000

,000

1.

0C

ondo

ms

to b

e pr

ovid

ed to

NM

S o

n de

man

d fro

m U

HM

G

7M

anua

l Vac

uum

Asp

iratio

n (M

VA

) D

oubl

e V

alve

**K

it-

5,6

00

UN

FPA

was

requ

este

d to

pro

vide

an

inte

rim s

uppl

y as

we

awai

t for

the

Wor

ld b

ank

proc

urem

ent b

ut th

ey h

ave

not b

een

able

to p

rovi

de s

o fa

r. W

B d

eliv

ery

of 4

600

expe

cted

by

Nov

embe

r 201

2

Mam

a K

it**

Kit

1,89

3

25

,000

0.

1

276

,000

NM

S h

as fr

amew

ork

cont

ract

s fo

r sup

ply

of m

ama

kits

. Wor

ld B

ank

2760

00 E

TA

Dec

201

2;

NM

S re

ports

that

the

dem

and

for m

aam

a ki

ts is

hig

her t

han

the

curr

ent A

MC

, of 2

5,00

0 w

hich

is

not

mee

ting

the

coun

try’s

nee

d. T

hey

expr

esse

d ne

ed fo

r sup

port

by p

rocu

ring

addi

tiona

l m

ama

kits

to m

eet t

he c

ount

ry’s

nee

ds.

8Fe

mal

e C

ondo

m**

1000

-

68

,000

Fe

mal

e co

ndom

s cu

rren

tly o

nly

dist

ribut

ed th

roug

h U

HM

G to

the

priv

ate

sect

or

9Le

vono

rges

trel 7

50 m

cg T

ab

(Em

erge

ncy

Con

trace

ptiv

e)**

Pac

k59

1,10

3

2

,001

29

5.4

Item

ove

r sto

cked

and

at r

isk

of e

xpiry

. Cur

rent

ly, n

o fu

rther

sup

ply

plan

.

10M

isop

rost

ol 2

00m

cg T

abs*

* 1

Tab

let

1,62

7,74

0

5

2 31

302.

7Ite

m o

ver s

tock

ed a

nd a

t ris

k of

exp

iry. C

urre

ntly

, no

furth

er s

uppl

y pl

an.

11G

ynae

colo

gica

l glo

ves

1 P

air

900

NM

S V

ote

116

has

them

on

Fram

ewor

k co

ntra

ct.

NM

S c

onfir

ms

that

they

hav

e pl

anne

d 11

Gyn

aeco

logi

cal g

love

s1

Pai

r90

0S

con

firm

s th

at th

eye

plan

ned

proc

urem

ent u

nder

the

WB

fund

s; 1

20,0

00 p

airs

(Lar

ge) a

nd 1

20,0

00 p

airs

(med

ium

).

Que

stio

ns o

rcla

rific

atio

ns?

E-m

ail t

oph

arm

acy@

heal

th.g

o.ug

orok

umu.

mor

ris@

heal

th.g

o.ug

Labo

rato

ryC

omm

oditi

es- R

eage

nts,

Kits

and

Con

sum

able

s(M

axM

OS

:10

,M

inM

OS

:5fo

rce

ntra

llev

el)

Not

e AM

C=

Aver

age

Mon

thly

Cons

umpt

ion;

NM

S=

Nat

iona

l Med

ical

Sto

res;

JMS

=Jo

intM

edic

al S

tore

;CP

HL

=Ce

ntra

l Pub

licH

ealth

Labo

rato

ries

Dri

tiU

itIn

vent

ory

NM

SIn

vent

ory

JMS

(Cdi

tLi

)To

tal

It

Est

imat

edA

vera

geM

thl

Est

imat

edM

onth

sfS

tk

(Ct

lQ

uant

ityon

Mon

ths

ofS

tk

Exp

ecte

dC

t

Que

stio

ns o

r cla

rific

atio

ns?

Em

ail t

oph

arm

acy@

heal

th.g

o.ug

or o

kum

u.m

orris

@he

alth

.go.

ug

Des

crip

tion

Uni

tIn

vent

ory

NM

Sat

30/0

7/20

12(C

redi

tLin

e)at

30/0

7/20

12In

vent

ory

(Cen

tral

Leve

l)M

onth

lyC

onsu

mpt

ion

ofS

tock

(Cen

tral

Leve

l)

Qua

ntity

onO

rder

Sto

ckon

Ord

er

Exp

ecte

dD

eliv

ery

Dat

eC

omm

ents

1C

arbo

-fuch

sin

solu

tion

1000

ml

337

337

216

1.6

795

3.7

20/0

8/20

12N

oA

larm

2M

ethy

lene

blue

0.5%

solu

tion

100m

l95

9529

80.

364

82.

2A

ug-2

012

As

aco

unte

r- c

onut

er s

tain

.Mak

esu

reTB

isco

mpl

ate.

NTL

Ppr

ovid

esbu

ffer s

tock

for t

his

com

mod

ity.N

oim

pend

ing

risk

ofst

ock

out.

3Fi

eld

stai

nA

solu

tion

1000

ml

1,15

91,

159

500

2.3

3,00

06.

0A

ug-2

012

No

risk

ofst

ock

4Fi

eld

stai

nB

solu

tion

1000

ml

1,21

71,

217

500

2.4

3,00

16.

0S

ep-2

012

No

risk

ofst

ock

5G

ram

Iodi

neso

lutio

n10

00m

lB

ottle

627

627

120

5.2

360

3.0

15/1

2/20

12O

k

6M

alar

iaR

apid

diag

nost

icki

ts(2

5te

sts)

Kit

24,2

7124

,271

10,0

002.

430

,000

3.0

30/0

8/20

12G

F?

7R

PR

Kit

100

test

spa

ckK

it99

9965

00.

25,

200

8.0

Aug

usta

ndO

ctob

er

Cur

rent

lyst

ocke

dou

t.C

ON

SU

MP

TIO

NO

FTH

ISIT

EM

HA

SS

HO

TU

PD

UE

TOV

AR

IOU

SP

RO

GR

AM

STH

AT

HA

VE

SY

PH

ILIS

TES

TIN

GA

SP

RE

RQ

UIS

ITE

(PM

TCT

SM

CE

TC)

7R

PR

Kit

100

test

spa

ckK

it99

9965

00.

25,

200

8.0

Oct

ober

20

12P

RO

GR

AM

STH

AT

HA

VE

SY

PH

ILIS

TES

TIN

GA

SP

RE

RQ

UIS

ITE

.(PM

TCT,

SM

CE

TC)

8U

nigo

ldra

pid

test

kit2

0te

sts

Kit

4,45

04,

450

500

8.9

4,50

09.

031

/12/

2102

CO

NS

UM

PTI

ON

OF

THIS

ITE

MH

AS

SH

OT

UP

DU

ETO

VA

RIO

US

PR

OG

RA

MS

THA

TH

AV

EH

IVTE

STI

NG

AS

PR

ER

QU

ISIT

E.(P

MTC

T,P

ITC

,SM

CE

TC)-

Hav

est

oppe

dIp

sfro

mpr

ocur

ing

buffe

r sto

ckin

the

spiri

tofh

arm

onis

atio

n.A

ll Ip

sar

epu

lling

from

NM

Sus

ing

the

faci

lity

whr

eth

eyrk

Nf

fki

nw

ork.

No

fear

ofo

vers

tock

ing.

9S

tat-p

ack

rapi

dte

stki

t(30t

ests

)K

it7,

097

7,09

71,

200

5.9

6,00

05.

030

/11/

2012

CO

NS

UM

PTI

ON

OF

THIS

ITE

MH

AS

SH

OT

UP

DU

ETO

VA

RIO

US

PR

OG

RA

MS

THA

TH

AV

EH

IVTE

STI

NG

AS

PR

ER

QU

ISIT

E.(P

MTC

T,P

ITC

,SM

CE

TC)

HIV

TES

TIN

GA

SP

RE

RQ

UIS

ITE

.(PM

TCT,

PIT

C,S

MC

ETC

)

Aug

usta

ndC

ON

SU

MP

TIO

NO

FTH

ISIT

EM

HA

SS

HO

TU

PD

UE

TOV

AR

IOU

SP

RO

GR

AM

STH

AT

HA

VE

10H

IVD

eter

min

eR

apid

Test

Kit(

100

test

s)K

it25

,783

25,7

839,

000

2.9

21,0

002.

3N

ovem

ber

2012

CO

NS

UM

PTI

ON

OF

THIS

ITE

MH

AS

SH

OT

UP

DU

ETO

VA

RIO

US

PR

OG

RA

MS

THA

TH

AV

EH

IVTE

STI

NG

AS

PR

ER

QU

ISIT

E.(P

MTC

T,P

ITC

,SM

CE

TC).

Impe

ndin

gst

ocks

from

GF

11P

arTe

cre

agen

tkit

(100

test

s)K

it-

-44

279

6.3

Aug

-201

2C

urre

ntly

stoc

ked

out.

Man

yo

the

hosp

itals

they

now

unab

leto

carr

you

tCD

4te

stin

gye

tsam

ple

fl

tis

Nd

tdi

tth

rd11

Par

Tec

reag

entk

it(1

00te

sts)

Kit

4427

96.

3A

ug-2

012

refe

rral

sys

tem

isve

rypo

or.N

eed

toex

pedi

teth

eor

ders

.

12H

eam

atol

ogy

Hum

an(H

umac

ount

)P

ack

3910

3.9

404

15/0

8/20

12

13H

eam

atol

ogy

Nih

onK

it22

012

18.3

AS

SE

SS

ME

NT

OF

CO

NS

UM

PTI

ON

RA

TES

TILL

INP

RO

GR

ES

SC

urre

ntco

nsup

tion

ison

lyfo

r M

ulag

o.H

ospi

tals

with

Nih

onsh

ould

been

cour

aged

toor

der.

How

ever

Nih

onis

aba

ck-u

pto

othe

r-

HIG

HR

ISK

OF

EX

PIR

Y

14C

hem

istry

Hum

anK

it-

1052

5.2

15/0

8/20

12

15Fa

csco

untr

eage

ntki

t(50

's)

Kit

--

30O

NP

RO

CU

RE

ME

NT

16C

D4

FAC

SC

alib

ur(5

0te

sts)

Kit

-O

NP

RO

CU

RE

ME

NT

17C

hem

istry

Cob

asK

it-

ON

PR

OC

UR

EM

EN

T17

Che

mis

tryC

obas

Kit

-O

NP

RO

CU

RE

ME

NT

Que

stio

ns o

r cla

rific

atio

ns?

Em

ail t

oph

arm

acy@

heal

th.g

o.ug

or o

kum

u.m

orris

@he

alth

.go.

ug

Min

istr

yof

Hea

lthTr

acer

Med

icin

es (M

ax M

OS

:6 M

inM

OS

:4 fo

rce

ntra

llev

el)

Not

e *A

vera

ge M

onth

ly C

onsu

mpt

ion

is e

stim

ated

usi

ng N

MS

issu

es d

ata

AM

C=

Aver

age

Mon

thly

Cons

umpt

ion;

NM

S=

Nat

iona

lMed

ical

Stor

es

Est

imat

edA

vera

geE

stim

ated

Mon

ths

Que

stio

ns o

rcla

rific

atio

ns?

Emai

l to

phar

mac

y@he

alth

.go.

ug

Des

crip

tion

Uni

tS

tock

onH

and

July

1,20

12

Est

imat

edA

vera

geM

onth

lyC

onsu

mpt

ion

Est

imat

edM

onth

sof

Sto

ck(C

entr

alLe

vel)

Qua

ntity

onO

rder

Mon

ths

ofS

tock

onO

rder

Exp

ecte

dD

eliv

ery

Dat

eC

omm

ents

1

Dep

o-P

rove

ra

(Med

roxy

prog

este

rone

Ace

tate

V

ial

1(M

edro

xypr

oges

tero

ne A

ceta

te

150m

g/m

l IN

J)*

Via

l

9686

016

3282

0.59

3206

8492

4295

056

.607

280

Stoc

k be

low

min

imum

stoc

k le

velb

ut la

rge

quan

titie

sar

eex

pect

edun

derN

MS

fram

ewor

k co

ntra

cts

2A

rtem

ethe

r-Lu

mef

antri

ne

20/1

20m

g ta

b (G

reen

),24

pac

k*30

Stri

ps

5501

1999

638.

67

0.0

-0.

0

3S

ulph

adox

ine-

Pyr

imet

ham

ine

500/

25m

g ta

b*10

00 ta

b

7208

1009

.666

67

7.1

-0.

0C

all o

fof3

.7 M

OS

issc

hedu

led

forN

ovem

ber2

012.

4C

otrim

oxaz

ole

480m

g10

00 ta

b23

,036

2.

280

,374

3.

5A

ug-2

012

4C

otrim

oxaz

ole

480m

g10

00 ta

b

5014

2

23,0

36

2.2

80,3

74

3.5

Aug

-201

2

5O

ral R

ehyd

ratio

n S

alts

for1

Litr

e25

7174

4

13,8

23

5.2

-0.

02.

3 M

OS

to b

e ca

lled

offi

n D

ecem

er20

12.

6M

easl

esV

acci

neV

ial

511,70

011

9,76

5 4.

3-

0.0

Que

stio

ns o

rcla

rific

atio

ns?

Emai

l to

phar

mac

y@he

alth

.go.

ug